0001193125-21-236976.txt : 20210805 0001193125-21-236976.hdr.sgml : 20210805 20210805072855 ACCESSION NUMBER: 0001193125-21-236976 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210805 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210805 DATE AS OF CHANGE: 20210805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AVROBIO, Inc. CENTRAL INDEX KEY: 0001681087 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 810710585 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38537 FILM NUMBER: 211146323 BUSINESS ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 7819626030 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE STREET 2: BLDG. 300, SUITE 201 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER COMPANY: FORMER CONFORMED NAME: AvroBio, Inc. DATE OF NAME CHANGE: 20160729 8-K 1 d220781d8k.htm 8-K 8-K
false 0001681087 0001681087 2021-08-05 2021-08-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2021

 

 

AVROBIO, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-38537   81-0710585

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

One Kendall Square

Building 300, Suite 201

Cambridge, MA 02139

(Address of principal executive offices, including zip code)

(617) 914-8420

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value per share   AVRO   Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02. Results of Operations and Financial Condition.

On August 5, 2021, AVROBIO, Inc. (the “Company”) issued a press release containing information about the Company’s results of operations for the three and six months ended June 30, 2021. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press release issued by AVROBIO, Inc., dated August 5, 2021.
104    The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

   

AVROBIO, INC.

Date: August 5, 2021     By:  

/s/ Geoff MacKay

      Geoff MacKay
      President and Chief Executive Officer
 EX-99.1 2 d220781dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

AVROBIO Reports Second Quarter 2021 Financial Results and

Provides Business Update

U.S. Food and Drug Administration granted Fast Track Designation to AVR-RD-04 for cystinosis

Company is planning to initiate multiple registration trials in 2022

Multiple data and regulatory updates anticipated over next 12 months

CAMBRIDGE, Mass., Aug. 5, 2021 — AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today reported financial results for the quarter ended June 30, 2021, and provided a business update.

“Data from the patients dosed to date across three indications continue to support our first-in-class, one-time investigational gene therapies as potentially transformative treatments for the more than 50,000 people worldwide living with the life-limiting lysosomal disorders we are researching,” said Geoff MacKay, president and CEO of AVROBIO. “In the second half of this year, we plan to share updated safety data from our ongoing clinical trials and plan to meet with regulatory agencies to discuss initiating potential registration trials in 2022 for Fabry disease, cystinosis and Gaucher disease type 3. With our Pompe disease and Hunter syndrome programs anticipated to enter the clinic in 2022, we remain fiercely committed to our purpose: to free people living with genetic disease from a lifetime of symptoms, chronic treatment and inevitable disease progression.”

Multiple program milestones anticipated over the next 12 months

AVR-RD-01 in Fabry disease:

 

•  

Two additional patients have been dosed in the FAB-GT trial since June 2021.

 

•  

AVROBIO intends to amend the FAB-GT Phase 2 trial protocol in August 2021 to include female participants and eliminate the antibody status exclusion as well as collect additional central nervous system (CNS) and cardiovascular data.

 

•  

Company plans to engage the U.S. Food and Drug Administration (FDA) to discuss a revised regulatory approach with the goal of initiating a registration trial in mid-2022.

 

•  

AVROBIO expects to present updated safety and tolerability data on all nine FAB-GT Phase 2 patients dosed to date in the fourth quarter of 2021 and updated efficacy and durability data for all dosed patients at the 18th Annual WORLDSymposium in February 2022.

AVR-RD-04 in cystinosis:

 

•  

FDA granted Fast Track Designation for AVR-RD-04 and cleared the Investigational New Drug (IND) application for the AVROBIO long-term follow up trial for patients dosed in the investigator-sponsored Phase 1/2 clinical trial1 of AVR-RD-04 (CTNS-RD-04) led by our collaboration partner at University of California San Diego (UCSD).

 

•  

Stephanie Cherqui, Ph.D., principal investigator of the investigator-sponsored Phase 1/2 clinical study, provided an update on the patients dosed to date in the Phase 1/2 trial at the virtual 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), May 11-14, 2021.

 

•  

AVROBIO expects to provide a clinical and regulatory update in the first quarter of 2022 and is planning to initiate a company-sponsored clinical trial in the second half of 2022, which it believes could potentially serve as a registration trial, subject to regulatory clearance.

Gaucher disease programs:

 

•  

AVR-RD-02 in Gaucher disease type 1:

 

  •  

The first patient dosed has completed the 48-week Phase 1/2 Guard1 trial and has enrolled in the long-term follow up trial, where patients will be followed for 14 years after the initial trial period. AVROBIO is currently enrolling additional patients in the Phase 1/2 trial.

 

  •  

AVROBIO expects to present updated safety data on Patient 1 in the fourth quarter of 2021 and a full program update in the first half of 2022.

 

•  

AVR-RD-06 in Gaucher disease type 3:

 

  •  

AVROBIO plans to engage regulatory agencies to discuss the regulatory strategy for AVR-RD-06, the company’s program for Gaucher disease type 3, a form of Gaucher disease associated with severe neurological symptoms.

 

  •  

The company is planning to initiate a potential registration trial of AVR-RD-06 in patients with Gaucher disease type 3 in the second half of 2022, subject to regulatory clearance.

Second Quarter 2021 Financial Results

AVROBIO reported a net loss of $31.4 million for the second quarter of 2021 as compared to a net loss of $28.8 million for the comparable period in 2020. This increase was driven by increased research and development expenses as well as increased general and administrative expenses.

 

 

1 

Collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 is funded in part by grants to UCSD from the California Institute for Regenerative Medicine (CIRM), Cystinosis Research Foundation (CRF) and National Institutes of Health (NIH).

Research and development expenses were $22.5 million for the second quarter of 2021 as compared to $20.9 million for the comparable period in 2020. This increase was driven by increased program development activities related to the advancement of the company’s pipeline as well as increased personnel-related costs resulting from an increase in employee headcount, which includes the impact of non-cash stock-based compensation.

General and administrative expenses were $8.9 million for the second quarter of 2021 as compared to $8.0 million for the comparable period in 2020. This increase was primarily due to an increase in employee headcount, which includes the impact of non-cash stock-based compensation, which was offset by a decrease in facilities costs, professional fees and legal fees.

As of June 30, 2021, AVROBIO had $226.4 million in cash and cash equivalents, as compared to $259.7 million in cash and cash equivalents as of Dec. 31, 2020. Based on the company’s current operating plan, AVROBIO expects its cash and cash equivalents as of June 30, 2021 will enable the company to fund its operating expenses and capital expenditure requirements into the first quarter of 2023.

About AVROBIO

Our vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable expression of therapeutic protein, even in hard-to-reach tissues and organs including brain, muscle and bone. Our ex vivo lentiviral gene therapy pipeline includes clinical programs in Fabry disease, Gaucher disease type 1 and cystinosis, as well as preclinical programs in Hunter syndrome, Gaucher disease type 3 and Pompe disease. AVROBIO is powered by our industry-leading plato® gene therapy platform, our foundation designed to deliver gene therapy worldwide. We are headquartered in Cambridge, Mass., with an office in Toronto, Ontario. For additional information, visit avrobio.com, and follow us on Twitter and LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “aims,” “anticipates,” “believes,” “could,” “designed to,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words and phrases or similar expressions that are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding our business strategy for and the

potential therapeutic benefits of our product candidates, the design, commencement, enrollment and timing of ongoing or planned clinical trials, clinical trial results, product approvals and regulatory pathways, our plans and expectations with respect to the development of AVR-RD-01, AVR-RD-04 and AVR-RD-06, including timing and design of potential registration trials for such product candidates, the intended use of such trials as our registration trials for these product candidates, and anticipated interactions with regulatory agencies, the timing of new clinical and regulatory updates, anticipated benefits of our gene therapy platform including potential impact on our commercialization activities, timing and likelihood of success, the expected benefits and results of our implementation of the plato® platform in our clinical trials and gene therapy programs, the expected safety profile of our investigational gene therapies, and statements regarding our financial and cash position and expected cash runway. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results in preclinical or early-stage clinical trials may not be indicative of results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements, or the scientific data presented.

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that any one or more of AVROBIO’s product candidates will not be successfully developed or commercialized, the risk of cessation or delay of any ongoing or planned clinical trials of AVROBIO or our collaborators, the risk that regulatory agencies may disagree with our anticipated development approach for our product candidates such as AVR-RD-01, AVR-RD-04 and AVR-RD-06, including that regulatory agencies may require additional clinical testing prior to initiating registration trials for such product candidates, that we may not be able to utilize our planned registration trial of AVR-RD-01 for full approval but instead be required to conduct additional testing, that we may be required to conduct our planned testing in a more time-consuming, expensive, challenging or otherwise different manner than we envision or have conducted for our existing trials, particularly in light of the FDA’s preference for clinical trials to be double-blinded and potentially include sham controls, the risk that we may not be able to utilize our envisioned surrogate endpoint to support full approval of AVR-RD-01 but instead be required to measure a different endpoint such as a clinical outcome, the risk that AVROBIO may not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that AVROBIO may not realize the intended benefits of our gene therapy platform, including the features of our plato® platform, the risk that our product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that we anticipate, the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or trials involving AVROBIO’s product candidates, the risk that we will be unable to obtain and maintain regulatory approval for our product candidates, the risk that the size and growth potential of the market for our

product candidates will not materialize as expected, risks associated with our dependence on third-party suppliers and manufacturers, risks regarding the accuracy of our estimates of expenses and future revenue, risks relating to our capital requirements and needs for additional financing, risks relating to clinical trial and business interruptions resulting from the COVID-19 outbreak or similar public health crises, including that such interruptions may materially delay our enrollment and development timelines and/or increase our development costs or that data collection efforts may be impaired or otherwise impacted by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause AVROBIO’s actual results to differ materially and adversely from those contained in the forward-looking statements, see the section entitled “Risk Factors” in AVROBIO’s most recent Quarterly Report, as well as discussions of potential risks, uncertainties and other important factors in AVROBIO’s subsequent filings with the Securities and Exchange Commission. AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Investor Contact:

Christopher F. Brinzey

Westwicke, an ICR Company

339-970-2843

chris.brinzey@westwicke.com

Media Contact:

Kit Rodophele

Ten Bridge Communications

krodophele@tenbridgecommunications.com

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

(Unaudited)

 

     June 30,      December 31,  
     2021      2020  

Cash and cash equivalents

    $ 226,438      $ 259,682  

Prepaid expenses and other current assets

      7,081        7,560  

Property and equipment, net

      3,990        3,064  

Other assets

      586        928  
  

 

 

     

 

 

  

Total assets

    $ 238,095      $ 271,234  
  

 

 

     

 

 

  

Accounts payable

    $ 2,029      $ 2,682  

Accrued expenses and other current liabilities

      14,924        13,932  

Deferred rent, net of current portion

      150        276  
  

 

 

     

 

 

  

Total liabilities

      17,103        16,890  

Total stockholders’ equity

      220,992        254,344  
  

 

 

     

 

 

  

Total liabilities and stockholders’ equity

    $ 238,095      $ 271,234  
  

 

 

     

 

 

  

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

 

     Three Months Ended June 30,     Six Months Ended June 30,  
     2021     2020     2021     2020  

Operating expenses:

         

Research and development

    $ 22,544     $ 20,866     $ 41,024     $ 39,140  

General and administrative

      8,831       7,991       17,235       16,306  
  

 

 

    

 

 

    

 

 

    

 

 

  

Total operating expenses

      31,375       28,857       58,259       55,446  

Loss from operations

      (31,375 )      (28,857 )      (58,259 )      (55,446 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Total other (expense) income, net

      (12 )      29       (27 )      645  
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss

    ($ 31,387 )    ($ 28,828 )    ($ 58,286 )    ($ 54,801 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Net loss per share — basic and diluted

    ($ 0.74 )    ($ 0.80 )    ($ 1.39 )    ($ 1.57 ) 
  

 

 

    

 

 

    

 

 

    

 

 

  

Weighted-average number of common shares outstanding — basic and diluted

      42,510       36,105       42,067       34,886  
 EX-101.SCH 3 avro-20210805.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 avro-20210805_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, Address Line Three Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 avro-20210805_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 d220781d8k_htm.xml IDEA: XBRL DOCUMENT 0001681087 2021-08-05 2021-08-05 false 0001681087 8-K 2021-08-05 AVROBIO, INC. DE 001-38537 81-0710585 One Kendall Square Building 300 Suite 201 Cambridge MA 02139 (617) 914-8420 false false false false Common Stock, $0.0001 par value per share AVRO NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Aug. 05, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001681087
Document Type 8-K
Document Period End Date Aug. 05, 2021
Entity Registrant Name AVROBIO, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-38537
Entity Tax Identification Number 81-0710585
Entity Address, Address Line One One Kendall Square
Entity Address, Address Line Two Building 300
Entity Address, Address Line Three Suite 201
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02139
City Area Code (617)
Local Phone Number 914-8420
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value per share
Trading Symbol AVRO
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d220781d8k.htm avro-20210805.xsd avro-20210805_lab.xml avro-20210805_pre.xml d220781dex991.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d220781d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d220781d8k.htm" ] }, "labelLink": { "local": [ "avro-20210805_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "avro-20210805_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "avro-20210805.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "avro", "nsuri": "http://www.avrobio.com/20210805", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d220781d8k.htm", "contextRef": "duration_2021-08-05_to_2021-08-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d220781d8k.htm", "contextRef": "duration_2021-08-05_to_2021-08-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three", "terseLabel": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.avrobio.com//20210805/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-21-236976-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-236976-xbrl.zip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end